UNSPSC 51111637: Evandamine

This classification denotes a lipooxygenase inhibitor with the molecular formula C11H16N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZG2L2878MD, chemically known as (- )-2-(3-amino-5-methyl-2-pyrazolin-1-yl)-4,5,6,7-tetrahydrobenzothiazole. but generally known as evandamine, which bears US NIH Compound Identifier 3038554. European Medicines Agency schedules Evandamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07353MIG. The term EVANDAMINE is an International Non-Proprietary Name.

UNSPSC 51111637 Evandamine, a Commodity code, covers pharmaceutical products and prescription fulfillment arrangements that state and local health agencies are beginning to source directly from manufacturers rather than through traditional pharmacy benefit managers and wholesalers. The Texas Health and Human Services Commission issued a Request for Information (RFI) on March 27, 2026, to explore vendor capabilities for implementing direct-to-manufacturer prescription programs that would bypass conventional intermediaries, reduce costs through negotiated net pricing without rebates, and enable value-based or outcomes-based contracting with self-insured employer and government health plans. State health agencies are the primary issuing bodies under this code, focused on restructuring pharmaceutical supply chains to improve efficiency and cost control within their pharmacy benefit programs.

Recent procurement activity under this code remains minimal and exploratory. The Texas HHS Commission's RFI (HHS0017013, response deadline April 3, 2026) represents the only identifiable state or local opportunity on record and functions as a preliminary market intelligence gathering phase rather than a committed procurement with budget allocation or formal competitive timeline. The RFI seeks vendor experience with direct contracting for self-insured employers and government health plans, ability to negotiate on net pricing models, and capability to support value-based agreements, but does not specify set-aside designations, funding amounts, or geographic concentration beyond Texas. No additional state or local solicitations under this code have been posted, suggesting that direct-to-manufacturer pharmaceutical procurement remains an early-stage initiative with limited near-term transactional activity.